A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy
Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
Following Restricted FDA Approval of Descovy As PrEP, TAG Calls on Gilead to Immediately Partner with Community for Research on Vaginal Exposure
ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis
A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito from Otsuka Pharmaceutical
by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB…
Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual…
Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls
By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Sucess
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …
Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines
By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting…